WJX

(6P)-N-(1,3-dimethyl-1H-pyrazole-4-sulfonyl)-6-[3-(3,3,3-trifluoro-2,2-dimethylpropoxy)-1H-pyrazol-1-yl]-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide

Created:2022-09-16
Last modified:  2022-10-19

Help

Find related ligands:

Chemical Details

Formal Charge0
Atom Count75
Chiral Atom Count1
Bond Count78
Aromatic Bond Count16
2D diagram of WJX

WebGL does not seem to be available.

This can be caused by an outdated browser, graphics card driver issue, or bad weather. Sometimes, just restarting the browser helps. Also, make sure hardware acceleration is enabled in your browser.

For a list of supported browsers, refer to http://caniuse.com/#feat=webgl.

Toggle HydrogenToggle Labels

Chemical Component Summary

Name(6P)-N-(1,3-dimethyl-1H-pyrazole-4-sulfonyl)-6-[3-(3,3,3-trifluoro-2,2-dimethylpropoxy)-1H-pyrazol-1-yl]-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide
SynonymsElexacaftor
Systematic Name (OpenEye OEToolkits)~{N}-(1,3-dimethylpyrazol-4-yl)sulfonyl-2-[(4~{S})-2,2,4-trimethylpyrrolidin-1-yl]-6-[3-[3,3,3-tris(fluoranyl)-2,2-dimethyl-propoxy]pyrazol-1-yl]pyridine-3-carboxamide
FormulaC26 H34 F3 N7 O4 S
Molecular Weight597.653
TypeNON-POLYMER

Chemical Descriptors

TypeProgramVersionDescriptor
SMILESACDLabs12.01O=S(=O)(NC(=O)c1ccc(nc1N1CC(C)CC1(C)C)n1ccc(OCC(C)(C)C(F)(F)F)n1)c1cn(C)nc1C
SMILESCACTVS3.385C[CH]1CN(c2nc(ccc2C(=O)N[S](=O)(=O)c3cn(C)nc3C)n4ccc(OCC(C)(C)C(F)(F)F)n4)C(C)(C)C1
SMILESOpenEye OEToolkits2.0.7Cc1c(cn(n1)C)S(=O)(=O)NC(=O)c2ccc(nc2N3CC(CC3(C)C)C)n4ccc(n4)OCC(C)(C)C(F)(F)F
Canonical SMILESCACTVS3.385 C[C@@H]1CN(c2nc(ccc2C(=O)N[S](=O)(=O)c3cn(C)nc3C)n4ccc(OCC(C)(C)C(F)(F)F)n4)C(C)(C)C1
Canonical SMILESOpenEye OEToolkits2.0.7 Cc1c(cn(n1)C)S(=O)(=O)NC(=O)c2ccc(nc2N3C[C@H](CC3(C)C)C)n4ccc(n4)OCC(C)(C)C(F)(F)F
InChIInChI1.06 InChI=1S/C26H34F3N7O4S/c1-16-12-25(5,6)35(13-16)22-18(23(37)33-41(38,39)19-14-34(7)31-17(19)2)8-9-20(30-22)36-11-10-21(32-36)40-15-24(3,4)26(27,28)29/h8-11,14,16H,12-13,15H2,1-7H3,(H,33,37)/t16-/m0/s1
InChIKeyInChI1.06 MVRHVFSOIWFBTE-INIZCTEOSA-N

Drug Info: DrugBank

DrugBank IDDB15444 
NameElexacaftor
Groups
  • approved
  • investigational
DescriptionElexacaftor (previously VX-445) is a small molecule, next-generation corrector of the cystic fibrosis transmembrane conductance regulator (CFTR) protein.[A187361] It received FDA approval in October 2019 in combination with [tezacaftor] and [ivacaftor] as the combination product Trikafta<sup>TM</sup>.[L9395] Elexacaftor is considered a next-generation CFTR corrector as it possesses both a different structure and mechanism as compared to first generation correctors like tezacaftor.[A187361] While dual corrector/potentiator combination therapy has proven useful in the treatment of a subset of CF patients,[A187358] their use is typically limited to patients who are homozygous for the _F508del-CFTR_ gene.[A187361] Elexacaftor, along with [VX-659], was designed to fill the need for an efficacious CF therapy for patients who are heterozygous for _F508del-CFTR_ and a gene that does not produce protein or produces proteins unresponsive to ivacaftor or tezacaftor.[A187361] The triple combination product Trikafta<sup>TM</sup>, manufactured by Vertex Pharmaceuticals, is the first product approved for the treatment of CF in individuals who are either homo- _or_ heterozygous for the _F508del-CFTR_ gene - this represents approximately 70[A187373]-90%[A187361,A187355] of all CF patients.
SynonymsElexacaftor
Brand Names
  • Kaftrio
  • Trikafta
IndicationElexacaftor, in combination with [ivacaftor] and [tezacaftor] as the combination product Trikafta<sup>TM</sup>, is indicated for the treatment of cystic fibrosis (CF) in patients 12 years of age and older who have at least one _F508del_ mutation in the CTFR gene.[L9395]
Categories
  • Cystic Fibrosis Transmembrane Conductance Regulator Correctors
  • Cytochrome P-450 CYP1A2 Inhibitors
  • Cytochrome P-450 CYP1A2 Inhibitors (strength unknown)
  • Cytochrome P-450 CYP2B6 Inhibitors
  • Cytochrome P-450 CYP2B6 Inhibitors (strength unknown)
ATC-CodeR07AX32
CAS number2216712-66-0

Drug Targets

NameTarget SequencePharmacological ActionActions
Cystic fibrosis transmembrane conductance regulatorMQRSPLEKASVVSKLFFSWTRPILRKGYRQRLELSDIYQIPSVDSADNLS...unknownpositive allosteric modulator
Cytochrome P450 3A4MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNI...unknownsubstrate,inhibitor
Cytochrome P450 3A5MDLIPNLAVETWLLLAVSLVLLYLYGTRTHGLFKRLGIPGPTPLPLLGNV...unknownsubstrate
Cytochrome P450 1A2MALSQSVPFSATELLLASAIFCLVFWVLKGLRPRVPKGLKSPPEPWGWPL...unknowninhibitor
Cytochrome P450 2B6MELSVLLFLALLTGLLLLLVQRHPNTHDRLPPGPRPLPLLGNLLQMDRRG...unknowninhibitor
View More
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
Pharos CHEMBL4298128
PubChem 134587348
ChEMBL CHEMBL4298128